// App-Quantinova.ai

BSH2020‐PO‐013 : Inhibition of myeloid cell leukaemia 1 (MCL1) overcomes bromodomain and extra‐terminal (BET) inhibition resistance in acute myeloid leukaemia (AML) cells

Researchers

Presenter

  • E. Ladikou

Principal Investigators

  • T. Chevassut

Medical Centers

  • Brighton and Sussex Medical School, Brighton, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Lymphomas

  • Multiple Myeloma

Biomarkers

  • Myeloid Cell Leukemia 1

  • B-cell lymphoma 2

  • B-cell lymphoma-extra large

  • cMYC

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved